Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.radonc.2024.110587 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and toxicity of Iopofosine I 131 (CLR 131) with external beam radiation therapy in recurrent or metastatic head and neck cancer: results of a phase 1 single-centre, open-label, single-arm, dose escalation and dose expansion study.
EBioMedicine
December 2024
Department of Human Oncology, UW School of Medicine and Public Health, Madison, WI, USA.
Background: Re-irradiation of recurrent head and neck cancer (HNC) is often limited by tumour adherence to critical structures and/or radiation tolerance of critical normal tissues. Iopofosine I 131 (CLR 131) is a targeted small molecular phospholipid ether (PLE) drug conjugate that delivers iodine-131 selectively to tumour cells. We conducted a phase 1, single-centre, open-label study to determine whether CLR 131 given with reduced dose of external beam radiation therapy (EBRT) would be tolerable and feasible.
View Article and Find Full Text PDFConsistency in reirradiation scenarios: Terminology, tissue recovery in calculations, units and reporting.
Radiother Oncol
January 2025
Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom.
Treatment of Locally Recurrent Rectal Cancer: A Review.
Cancer J
July 2024
From the Department of Radiation Oncology.
Up to 10% of patients with locally advanced rectal cancer will experience locoregional recurrence. In the setting of prior surgery and often radiation and chemotherapy, these represent uniquely challenging cases. When feasible, surgical resection offers the best chance for oncologic control yet risks significant morbidity.
View Article and Find Full Text PDFSalvage low-dose-rate brachytherapy for locally recurrent prostate cancer after definitive irradiation.
Clin Transl Radiat Oncol
September 2024
Radiotherapy Department, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
Purpose: The optimal management of locally recurrent prostate cancer after definitive irradiation is still unclear but local salvage treatments are gaining interest. A retrospective, single-institution analysis of clinical outcomes and treatment-related toxicity after salvage I-125 low-dose-rate (LDR) brachytherapy (BT) for locally-recurrent prostate cancer was conducted in a Comprehensive Cancer Center.
Patients And Methods: A total of 94 patients treated with salvage LDR-BT between 2006 and 2021 were included.
Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial.
JAMA Oncol
July 2024
Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio.
Importance: Intensity-modulated radiation therapy (IMRT) reirradiation of nonmetastatic recurrent or second primary head and neck squamous cell carcinoma (HNSCC) results in poor progression-free survival (PFS) and overall survival (OS).
Objective: To investigate the tolerability, PFS, OS, and patient-reported outcomes with nivolumab (approved standard of care for patients with HNSCC) during and after IMRT reirradiation.
Design, Setting, And Participants: In this multicenter nonrandomized phase 2 single-arm trial, the treatment outcomes of patients with recurrent or second primary HNSCC who satisfied recursive partitioning analysis class 1 and 2 definitions were evaluated.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!